Oral Glucosestimulation After Gastric Bypass Surgery

NCT ID: NCT01851616

Last Updated: 2013-05-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to examine gastric emptying and satiety hormones after oral glucose stimulation in 2 different concentrations in morbidly obese patients after Roux-en-Y-gastric-Bypass.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After gastric bypass many patients suffer from early and/or late dumping syndrome as a reaction to carbohydrate rich meals. Gastric emptying after bypass is accelerated and nutrition enters the intestine faster, which leads to osmotically driven fluid shifts from the blood to the lumen. Late dumping occurs 1-3 h after eating, and is caused by hyperinsulinemia and is therefore characterized by symptoms of hypoglycemia like weakness, sweating, and dizziness. Many people have both types. In most studies examining satiety hormones after oral glucose stimulation in non-operated patients, glucose loads of 50-75g are used. For a measurable GLP-1 rise a threshold of 2 kcal/min. at the intestine is needed. After gastric bypass gastric emptying is accelerated and less glucose is necessary to reach this threshold. The "threshold load" and "tolerable load without dumping symptoms" is not yet know.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glucose 25g

25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)

Group Type ACTIVE_COMPARATOR

25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)

Intervention Type DIETARY_SUPPLEMENT

Glucose 10g

10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)

Group Type ACTIVE_COMPARATOR

10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)

Intervention Type DIETARY_SUPPLEMENT

10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 6 weeks post gastric bypass surgery,
* non-diabetic patient

Exclusion Criteria

* smoker,
* diabetes,
* gastrointestinal motility disorder,
* medication influencing gastric emptying
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christoph Beglinger, Prof.

Role: PRINCIPAL_INVESTIGATOR

University of Basel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital of Basel

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EKBB 298/12/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.